Product Description
Nonsteroidal FXR Agonist
Mechanisms of Action: FXR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, France, Japan, Puerto Rico, Spain, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Cholangitis, Sclerosing
Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WAYFIND | P2 |
Active, not recruiting |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2024-11-12 |
|
| 2021-001445-12 | P2 |
Active, not recruiting |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2024-08-27 |
|
| jRCT2071210112 | P2 |
Recruiting |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2024-07-31 |
|
| JapicCTI-194804 | P3 |
Active |
Cholangitis, Sclerosing |
2023-02-28 |